Alpelisib plus fulvestrant in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A

被引：2
|
作者：
Ciruelos, Eva M.
Lerebours, Florence
Rugo, Hope S.
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Prat, Aleix
Bachelot, Thomas
Neven, Patrick
Park, Yeon Hee
Turner, Nicholas
Juric, Dejan
Gu, Ennan
Arce, Christina H.
Akdere, Murat
Chia, Stephen
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-18-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-03
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (vol 22, pg 489, 2021)
    Rugo, H. S.
    Lerebours, F.
    Ciruelos, E.
    LANCET ONCOLOGY, 2021, 22 (05): : E184 - E184
  • [32] EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) plus /dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL).
    Gradishar, William John
    Farooki, Azeez
    Giridhar, Karthik
    Moore, Heather
    Johnston, Abigail
    Miller, Michelle Kristine
    Wang, Craig
    Reising, Albert
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
    Rugo, Hope S.
    Andre, Fabrice
    Park, Yeon Hee
    Drullinsky, Pamela
    Loibl, Sibylle
    Cardoso, Fatima
    Mason, Ginny
    Aubel, Dawn
    Lorenzo, Ines
    Akdere, Murat
    Ciruelos, Eva M.
    BREAST, 2021, 59 : S49 - S49
  • [34] A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
    Andre, F.
    Kaufman, B.
    Juric, D.
    Ciruelos, E.
    Iwata, H.
    Mayer, I. A.
    Conte, P.
    Rugo, H. S.
    Loibl, S.
    Rubovszky, G.
    Tesch, H.
    Inoue, K.
    Lu, Y-S.
    Ryvo, L.
    Longin, A-S.
    Mills, D.
    Wilke, C.
    Germa, C.
    Campone, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
    Andre, F.
    Kaufman, B.
    Juric, D.
    Ciruelos, E. M.
    Iwata, H.
    Mayer, I. A.
    Rugo, H. S.
    Conte, P.
    Liobl, S.
    Rubovszky, G.
    Inoue, K.
    Tesch, H.
    Lu, Y-S
    Ryvo, L.
    Longin, A-S
    Mills, D.
    Wilke, C.
    Germa, C.
    Campone, M.
    CANCER RESEARCH, 2017, 77
  • [36] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [37] Real-world effectiveness of alpelisib (ALP) plus fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2 negative (HER2-) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
    Turner, S.
    Chia, S. K. L.
    Kanakamedala, H.
    Hsu, W-C.
    Park, J.
    Chandiwana, D.
    Ridolfi, A.
    Yu, C-L.
    Zarate, J. P.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S366 - S366
  • [38] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [39] Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (Expression of Concern of Vol 22, Pg 489, 2021)
    不详
    LANCET ONCOLOGY, 2024, 25 (02): : e42 - e42
  • [40] Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S15 - S16
12345